.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Boehringer Ingelheim
QuintilesIMS
Accenture
Baxter
Queensland Health
Covington
Dow
Cipla

Generated: September 19, 2017

DrugPatentWatch Database Preview

Baxter Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has one hundred and ninety-two approved drugs.

There are six US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are one hundred and fifteen patent family members on BAXTER HLTHCARE drugs in thirty-five countries.

Summary for Applicant: Baxter Hlthcare

Patents:6
Tradenames:302
Ingredients:109
NDAs:192
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER
calcium chloride; dextrose; lactic acid; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride
INJECTABLE;INJECTION021703-004Oct 25, 2006RXYesYes► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
sodium chloride
INJECTABLE;INJECTION020178-002Dec 7, 1992APRXYesNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
dobutamine hydrochloride
INJECTABLE;INJECTION020255-005Oct 19, 1993APRXYesYes► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
CYTOXAN
cyclophosphamide
INJECTABLE;INJECTION012142-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL017512-007Jul 9, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
PLASMA-LYTE A IN PLASTIC CONTAINER
magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate
INJECTABLE;INJECTION017378-002Nov 22, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
amino acids; calcium chloride; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride
INJECTABLE;INJECTION020678-011Mar 26, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride
INJECTABLE;INJECTION020147-008Oct 23, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare Corp
BUPIVACAINE HYDROCHLORIDE
bupivacaine hydrochloride
INJECTABLE;SPINAL207266-001Jul 25, 2016APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
theophylline
INJECTABLE;INJECTION018649-005Jul 26, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Baxter Hlthcare

Paragraph IV activity for BAXTER HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
esmolol hydrochloride
Injection10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags
BREVIBLOC
1/31/2014
desflurane
Inhalation99.90%
SUPRANE
9/11/2008

Non-Orange Book Patents for Baxter Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,886,789 Peritoneal dialysis and compositions for use therein► Subscribe
9,750,822Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
8,410,077Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Baxter Hlthcare Drugs

Country Document Number Estimated Expiration
Spain2378306► Subscribe
Norway850603► Subscribe
Israel208956► Subscribe
European Patent Office0115911► Subscribe
South Africa8501230► Subscribe
Spain8700942► Subscribe
Slovakia12782002► Subscribe
Austria53765► Subscribe
United Kingdom2154469► Subscribe
Japan2010024249► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
128Luxembourg► SubscribePRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
2016000035Germany► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, ODER EIN ESTER-PRODRUG DAVON.; REGISTRATION NO/DATE: EU/1/15/1059 20151119
00612Netherlands► SubscribePRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
595Luxembourg► SubscribePRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
56/2007Austria► SubscribePRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES
C0041Belgium► SubscribePRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
AstraZeneca
QuintilesIMS
Colorcon
McKinsey
Medtronic
US Department of Justice
US Army
Julphar
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot